Literature DB >> 26151231

Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.

Shuang Han1, Fei-Fei Zhang2, Hai-Yan Qian1, Li-Li Chen1, Jian-Bin Pu1, Xin Xie2, Jian-Zhong Chen1.   

Abstract

The cannabinoid type 2 receptors (CB2Rs) play crucial roles in inflammatory diseases. There has been considerable interest in developing potent and selective ligands for CB2R. In this study, quinoline-2,4(1H,3H)-dione analogs have been designed, synthesized, and evaluated for their potencies and binding properties toward the cannabinoid type 1 receptor (CB1R) and CB2R. C5- or C8-substituted quinoline-2,4(1H,3H)-diones demonstrate CB2R agonist activity, while the C6- or C7-substituted analogs are antagonists of CB2R. In addition, oral administration of 21 dose-dependently alleviates the clinical symptoms of experimental autoimmune encephalomyelitis in a mouse model of multiple sclerosis and protects the central nervous system from immune damage. Furthermore, the interaction modes predicted by docking simulations and the 3D-QSAR model generated with CoMFA may offer guidance for further design and modification of CB2R modulators.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26151231     DOI: 10.1021/acs.jmedchem.5b00227

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Development of Quinazoline/Pyrimidine-2,4(1H,3H)-diones as Agonists of Cannabinoid Receptor Type 2.

Authors:  Hai-Yan Qian; Zhi-Long Wang; You-Lu Pan; Li-Li Chen; Xin Xie; Jian-Zhong Chen
Journal:  ACS Med Chem Lett       Date:  2017-05-01       Impact factor: 4.345

2.  Cannabinoid-Based Medicines and Multiple Sclerosis.

Authors:  Clementina Manera; Simone Bertini
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation.

Authors:  Eric W Bow; John M Rimoldi
Journal:  Perspect Medicin Chem       Date:  2016-06-28

Review 4.  Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis.

Authors:  Francesca Gado; Maria Digiacomo; Marco Macchia; Simone Bertini; Clementina Manera
Journal:  Medicines (Basel)       Date:  2018-08-15

Review 5.  Molecular Targets of Cannabinoids Associated with Depression.

Authors:  Pradeep Paudel; Samir Ross; Xing-Cong Li
Journal:  Curr Med Chem       Date:  2022       Impact factor: 4.740

Review 6.  Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders.

Authors:  Gemma Navarro; Paula Morales; Carmen Rodríguez-Cueto; Javier Fernández-Ruiz; Nadine Jagerovic; Rafael Franco
Journal:  Front Neurosci       Date:  2016-09-13       Impact factor: 4.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.